Patients diagnosed with bacterial lower respiratory tract infections or UTIs were randomly assigned to receive either biapenem ( 300 mg every 12 h ) or meropenem ( 500 mg every 8 h ) by intravenous infusion for 7 to 14 days according to their disease severity .